0222 GMT - IHH Healthcare's Turkish unit is likely to maintain its growth momentum despite political uncertainty there, Maybank Investment Bank analysts Nur Natasha Ariza and Yin Shao Yang say in a note. While accounting adjustments related to hyperinflation may weigh on reported earnings amid the Turkish lira's depreciation, core earnings should remain resilient, they say. The Acibadem unit benefits from foreign-currency-denominated medical tourism and steady private healthcare spending, they say. Contributing 30% of IHH's 2024 revenue, the Turkey business is projected to see 9% Ebitda growth in 2025, helped partly by stable in-patient volumes, they add. The analysts remain positive on Acibadem's non-lira income and IHH's other key segments. Maybank maintains a buy rating on IHH and keeps its target price at MYR7.97. Shares are unchanged at MYR6.91. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
March 27, 2025 22:22 ET (02:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。